Overview

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Status:
Recruiting

Trial end date:
2021-11-14

Target enrollment:
0

Participant gender:
All

Summary

This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir. Dabigatran is being utilized as a P-gp substrate

Phase:

Phase 1

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Pfizer

Treatments:

Dabigatran
Ritonavir

Criteria

Inclusion Criteria:

- Body Mass Index (BMI) of 17.5 to 30.5 kg.m2; and a total body weight >50 kg (110 lbs)

- Female participants must have a negative pregnancy test

Exclusion Criteria:

- Positive test for SARS-Co-V2 at the time of screening or Day -1

- Active pathological bleeding or risk of bleeding

- Positive urine drug test

- History of sensitivity to heparin or heparin induced thrombocytopenia

- Participants who have been vaccinated for COVID-19 in the past 7 days